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Abstract
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Objective—To assess the role of sexual relationships on levels and patterns of adherence to
medication for pre-exposure prophylaxis (PrEP) against HIV.
Methods—We enrolled 1,147 HIV-negative individuals in long-term serodiscordant
relationships at three sites in Uganda from the Partners PrEP Study- a randomized placebocontrolled trial of daily oral tenofovir and emtricitabine/tenofovir. We used generalized estimation
equations to assess the effects of sexual relationships on low adherence (<80%) and on gaps in
adherence.
Results—Fifty-three percent were male, 51% were 18-34 years and 24% were polygamous.
Participants who reported sex in the past month with someone other than their primary partner and
with <100% condom use were more than twice as likely to have low adherence (aOR 2.48, 95%
CI: 1.70-3.62) compared to those who had sex with only their primary partners and 100% condom
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use. Using the same reference group, those who abstained from sex in the previous month had
30% increased odds of low adherence (aOR 1.30, 95% CI: 1.05-1.62), and participants in nonpolygamous marriages who reported sex with both their primary and other partners and <100%
condom use were almost twice as likely to be low adherers (aOR 1.76, 95% CI: 1.01-3.08). At
least one 72-hour gap in adherence was seen in 598 participants (54.7%); 23.2% had at least one
one-week gap.
Conclusions—Risk of low overall adherence was higher in participants who reported sex
outside primary partnerships and suboptimal condom use, as well as in those who abstained from
sex. Adherence gaps were common, potentially creating risk for HIV acquisition.
Keywords
HIV pre-exposure prophylaxis; sexual behavior; adherence
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Introduction
HIV antiretroviral medications have been shown to reduce the transmission of the virus
when used for prophylaxis by HIV-negative individuals. 1-3 Based on these studies, the US
Food and Drug Administration (FDA) approved the use of tenofovir/emtricitabine; an
antiretroviral drug for pre-exposure prophylaxis (PrEP) by HIV-negative individuals with a
high risk of acquiring sexually transmitted HIV. 4 PrEP is now one of the few available HIV
prevention strategies in a field where vaccines and a cure have long been elusive.

Author Manuscript

Adherence to prescribed antiretroviral medication is known to be vital to successful viral
suppression and better clinical outcomes in HIV treatment settings. 5 Additionally,
adherence has been identified to be a key component of effective PrEP. 6 Poor adherence to
assigned medication is likely the primary reason for the null findings in the FEM-PREP and
VOICE studies, which assessed the efficacy of oral and topical tenofovir for HIV preexposure prophylaxis among heterosexual African women. 7
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Because PrEP is a new tool in HIV prevention, there are limited data on the associations of
adherence to this medication. However we recently reported that several factors including
age, heavy alcohol use, being in a polygamous marriage and sexual behavior might affect
adherence to HIV PrEP. 8 For the purposes of this study polygamy status was defined at
baseline and referred to one of two situations: 1) an HIV-negative man with more than one
wife, one of whom was HIV-positive, or 2) an HIV-negative woman whose HIV-infected
husband had more than one wife. Marriage was be defined by law, religious or local custom.
We assessed quarterly sexual behavior via interviewer-administered questionnaires and
quarterly adherence was assessed using the medication event monitoring system (MEMS:
Aardex, Switzerland). We found that HIV-negative participants who reported sex with only
people other than their primary sexual partners were twice as likely to have low rates of
adherence as compared to those who only reported sex with their primary partners (aOR 2.3,
95% C.I: 1.3 to 3.8). In a second study using SMS surveys for assessing sexual behavior 9,
participants who did not have sex on a particular day were almost twice as likely to miss a
dose of PrEP medication on that same day (aOR 1.87, 95% C.I: 1.35 to 2.60).

J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.

Kintu et al.

Page 3

Author Manuscript

To better understand the relationship between sexual behavior and adherence to PrEP, in this
study, we assessed the associations of sexual behavior with monthly adherence rates, which
may better assess short-term effects of sexual behavior, as well as with patterns of adherence
to PrEP. Patterns may be more informative than summary measures of adherence (e.g.,
median values) because lengthy gaps may expose an individual to more risk for HIV
acquisition compared to occasional missed doses. 10 We also explore the effect condom use
on adherence within all strata of sexual behavior. We further evaluated the influence of
polygamy within strata of sexual behavior to explore more closely the role of polygamy on
adherence to PrEP.

Methods
Study setting and population

Author Manuscript
Author Manuscript

We analyzed data from the Partners Ancillary Adherence Study, a sub-study of the Partners
PrEP Study. 1 The Partners PrEP Study was a multisite, phase III, randomized, double-blind,
placebo-controlled clinical trial that assessed the efficacy and safety of tenofovir (TDF) and
emtricitabine/tenofovir (FTC/TDF) for pre-exposure prophylaxis against HIV acquisition.
This clinical trial enrolled 4758 heterosexual serodiscordant couples at four sites in Kenya
and five sites in Uganda. Heterosexual couples were defined as “sexual partners of the
opposite gender who were married, had been living together, or otherwise considered each
other a primary partner”. The adherence study took place at three of the Ugandan sites
including Kampala (an urban setting) and Kabwohe and Tororo (rural settings; Figure 1).
We have previously described details of this study 8, but briefly, we enrolled 1147 HIVnegative individuals in long-term serodiscordant relationships. All PrEP study participants at
these sites were eligible for participation as long as they consented for study procedures and
had at least six or more months of follow-up in the parent clinical trial. Enrollment was
offered on a rolling basis and all participants provided written informed consent. In addition
to monthly follow up visits at the clinics, we conducted unannounced home visits for pill
counts monthly for the first 6 months and then quarterly thereafter. We also used the
medication event monitoring system [MEMS] to monitor the date and time of pill bottle
openings. Lastly, participants with <80% monthly adherence to PrEP were started on multisession adherence intervention. 11 Data for this analysis was censored at July 10, 2011, the
date of unbinding of the placebo arm.
Ethical statement
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The study was approved by the institutional review boards of participating study sites and
those of Massachusetts General Hospital/Partners Healthcare and of the University of
Washington.
Assessment of sexual behavior
Sexual behavior was assessed via interviewer-administered questionnaires completed at
monthly clinic visits. Face-to-face interviews have not been validated in a PrEP setting but
have been shown to consistently assess sexual behavior. 12 At each visit, study participants
met with counselors and discussed several issues relating to HIV-discordancy including
sexual behavior in the past month. The interviewers queried the number of sexual acts,
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condom use, and sexual acts with anyone besides the primary partner. Whenever ‘sex’ or
‘sexual intercourse’ was stated in a question, it included vaginal and anal sex, but not oral
sex. Interviews were conducted in either English or in a local language of a participant's
preference and participants were given the option of being interviewed by a counselor of
their choice.
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We categorized monthly sexual behavior as follows: participants who abstained, those who
had sex with only their primary partners, those who had sex with only other partners (but not
with their primary partner) and those that had sex with both the primary and other partner(s).
Each of the above categories was dichotomized into either 100% condom use or <100%
condom use. The “other partner” category included participants who in the previous month
did not have sex with their primary partner but reported sex with someone else. We were
unable to stratify this category by polygamy status at baseline due to small numbers. The
number of participants was sufficient however to make this stratification for the category
reporting sex with both the primary and other partner(s).
Assessment of adherence
Monthly adherence to PrEP medication was assessed using the medication event monitoring
system [MEMS]. This system uses an electronic microchip in the cap of a pill bottle to
record dates and times the pill bottle was opened and closed. The underlying assumption is
that every opening and closure of the pill bottle translates to a swallowed dose of the study
drug. Recorded adherence data was then downloaded during monthly clinic visits. Although
MEMS is a proxy measure and is subject to misclassification, it allows for assessment of
adherence patterns by documenting daily pill taking behavior 13 and has been shown to have
a high positive predictive value of treatment outcomes. 14

Author Manuscript

We assessed execution of adherence as a dichotomous variable, with 80% or greater
adherence defined as ‘high adherence’ and < 80% adherence defined as ‘low adherence’.
The level of adherence required for effective PrEP is not known. However, we recently
found 100% PrEP efficacy if participants' adherence rates are maintained at 80% and
above. 8 We also assessed patterns of adherence (i.e., the number of periods of at least 48
hours, 72 hours and 1 week during with the pill bottle was unopened). We looked at a range
of patterns because there is limited data on how much tenofovir must be present in blood
and tissue to offer protection against HIV. Data are also limited on how gaps in adherence
before and after achievement of stable states affect this protection. Using the heuristic that
drugs remain in the body for about 4 half-lives 15, it is likely that tenofovir (half life ∼ 17
hours) is undetectable after a gap of 68 hours, or approximately three days.

Author Manuscript

Assessments of other covariates
We collected baseline data on the study participant's age, gender, social economic status and
level of education, all of which have been shown to be associated with adherence in HIV
treatment settings. 16 We assessed partnership characteristics including how long the couple
had been living together, the number of children they had, whether one of them was in a
polygamous marriage and how long they had known that they were HIV discordant. Social
economic status was assessed using the Filmer-Pritchett index, which uses household items

J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
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to estimate wealth. 17 For this study, the wealth index for a couple's home reflected the
presence of a concrete floor, running water, electricity, a television and a house with two or
more rooms of residence.
Time varying characteristics assessed included heavy alcohol use, depression, number of
study drug side effects, the participant's perceived risk of HIV acquisition and CD4 cell
counts of the HIV-infected partner. Depression was assessed using the Hopkins Symptom
Checklist, a functional impairment assessment instrument that can be used to approximate a
DSM-IV depression diagnosis, which has been validated in similar populations. 18 Heavy
alcohol use was assessed using the Rapid Alcohol Problems Screen that has been shown to
have good sensitivity and specificity in identifying detrimental drinking patterns and has
cross-nation validity. 19

Author Manuscript

Statistical analysis
We performed bivariate analyses between each possible covariate and adherence using
generalized estimating equations (GEE). Monthly adherence execution was modeled using a
binomial distribution, whereas adherence patterns were modeled with a Poisson distribution.
For model selection, the initial multivariate model included all variables with a p-value
≤0.20 from the bivariate analyses. Starting with variables with the highest p-values we
assessed the scale of maximum likelihood, one at a time and dropped those with p-values
>0.10 from the final multivariate model. We used a similar method to assess possible
interaction effects between sexual behaviors with age, gender, study site and social
economic status, all chosen a priori and used a p-value of <0.10 as a cutoff for statistical
significance. Data were analyzed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
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Results
Study participants
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A total of 1,751 HIV-negative participants enrolled in the parent clinical trial at the three
sites. Of these, 1,182 were offered participation in the adherence study and 1,147 (97%)
were enrolled. Reasons for not being offered participation included having less than 6
months remaining for follow-up while on study drug, logistical reasons that would make
study procedures difficult to conduct and stopping of the parent clinical trial before
participation could be offered. Thirty-five participants did not meet the criteria for
enrollment resulting in a final analysis dataset of 1,093 participants (Table 1). Of these,
53.4% were male, 51.2% were aged between 18 and 34 years, the median number of years
living with the HIV-positive partner was 8.5 years, and 24.2% were in polygamous
marriages. The mean follow-up duration was 11 months.
Overall adherence and sexual behavior
A total of 402 (36.7%) participants had at least one month with <80% adherence; this
translated into 13.3% of the observed months of low adherence. Levels of adherence are
presented by category of sexual activity and condom use in Table 2. Participants who
reported sex with other partners only (i.e., no sex with their primary sexual partner) and also
reported < 100% condom use (N=92) were more than twice as likely to be low adherers as
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compared to those who had sex only with their primary partners with 100% condom use
(aOR 2.48, 95% CI: 1.70 to 3.62). The number of other sexual partners had no effect on
odds for low adherence (OR: 0.98, 95% CI: 0.68-1.40). Using the same reference group,
those who abstained from sex in the previous month (N=465) had 30% increased odds of
low adherence (aOR 1.30, 95% CI: 1.05 to 1.62). Participants who reported sex with both
their primary and other partners (not including polygamous marriages) with < 100% condom
use (N=60) were almost twice as likely to be low adherers (aOR 1.76, 95% CI: 1.01 to 3.08).
However, those with similar sexual behavior in the past month but in polygamous marriages
did not have significantly higher odds of low adherence (aOR: 1.10 95% CI: 0.49 to 2.53).
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Participants who reported sex with only their primary partners were more likely to have
100% condom use as compared to those who had sex with both their primary partners and
other partner(s), and with those who had sex with only other partners (79%, 33% and 36%
respectively). Those with low or moderate concern of contracting HIV had 41% lower odds
of low adherence as compared to those who had no concern of HIV acquisition. Men were
34% more likely to be low adherers than women. We did not find any significant interaction
effects of sexual behavior with age (P=0.91), social economic status (P=0.23) or study site
(P=0.17) on the likelihood of having <80% monthly adherence to PrEP.
Patterns of adherence
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Prevalence of gaps in adherence by sexual behavior is presented in Table 3. A total of 598
(54.7%) of the participants had at least one gap of 72 consecutive hours of non-adherence
and 254 (23.2%) of these also had at least one one-week gap of non-adherence. Of the
participants who reported <100% use of condoms in a previous month (N=546), 38.8% had
at least one 72-hour gap in adherence in that month and 17% had a one-week gap in
adherence in that month.
Participants who reported sex with other partners only and <100% condom use had 50%
higher odds of having at least one 72-hour gap in adherence as compared to those who had
sex with only their primary partners with 100% condom use (aOR 1.50, 95% CI: 1.19 to
1.91), while those who abstained from sex in the previous month had 17% elevated odds
(aOR=1.17, 95% CI: 1.01 to 1.35; Table 4). Adherence gaps of 72 hours were not associated
with reporting sex with both primary and other partners in the previous month, regardless of
polygamy status. We found similar results when assessing odds of having 48-hour gaps in
adherence (data not shown). Men were more likely to have had a one-week gap as compared
to women (aOR: 1.54, 95% CI: 1.04 to 2.27).
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Discussion
In this prospective observational study within a randomized clinical trial, HIV-negative
participants who reported sex with people other than their primary partner and those who
abstained from sexual activity in the previous month were more likely to be low adherers.
We found similar, although somewhat weaker associations between sexual activity and gaps
in adherence. Our findings also indicate that <100% condom use was more common in
participants who reported sex with only other partners and that participants in polygamous
marriages did not have increased odds of being low adherers.
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These findings extend results from our previous study. 8 The current study however,
observed somewhat weaker associations among participants that had abstained in the past
month, which suggests that the association of abstinence with adherence may be stronger if
this sexual behavior is sustained over a longer period (in this case, quarterly versus
monthly). We also found that participants who had sex with only other partners had the
highest odds of low adherence and having gaps of non-adherence. We are however unable to
distinguish whether this other partner was a new sexual partner or a partner in a polygamous
marriage. Nonetheless, these findings indicate that participants who had sex with only other
partners are more likely to be low adherers. A similar pattern has been observed in some
HIV treatment settings, where patients with risky sexual behaviors are also more likely to be
poor adherers to therapy. 20, 21 Also, the highest odds of low adherence were observed in
participants who had sex with only other partners and in the same month also had less than
100% condom use. Further research is needed on the dynamics influencing condom use with
primary partners (HIV-infected) and with other partners. However, one possible explanation
for both lower adherence and <100% condom use is low perceived risk of acquiring HIV
from the other partner.
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To our knowledge no study has explicitly assessed the role of polygamy on adherence.
Several studies have however found that polygamy offers a protective effect against HIVacquisition. 22, 23 Our previous findings showed that participants in polygamous marriage
had a 60% reduced odds for low adherence as compared to those from monogamous
marriages. 8 We did not find a protective effect in this study but did find no increased risk
among polygamous partners. We hypothesize that HIV-negative partners in discordant and
polygamous marriages receive extra social support to adhere to PrEP so as to prevent
transmission of HIV within the polygamous marriage. This concept is consistent with our
recent findings that spousal support plays a key role in PrEP adherence. 24 The lack of a
protective effect in our study could be multifactorial. First, we had small numbers of people
in these stratifications. Secondly, the one-month exposure period might not be long enough
to assess the protective effect that was observed in quarterly assessment of sexual behavior
on adherence.
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This is the first study to assess the effect of sexual behavior on patterns of adherence.
Though previous studies have shown that participants in Partners PrEP Study had high rates
of adherence 8, we found that many participants had gaps of not taking their medication.
Such intermittent dosing is likely to increase the risk of acquiring HIV since every
subsequent day of non-adherence results in a lower concentration of active drug. This
increased risk is consistent with findings from the FEM-PrEP study that showed high rates
of inconsistent use of the study drug that could have contributed to the lack of a protective
effect in the active study arms. 25 Some of the observed gaps, however, could have been due
to pocket doses (i.e., removal of multiple tablets with one opening for later use) —a wellestablished limitation of electronic adherence measurement, and may not reveal true gaps in
adherence. The correlation of adherence gaps with other potentially risky sexual behaviors,
like sex with other partners, suggests that many are real. Additionally, we do not know if
these gaps in adherence were covered by other forms of HIV prevention (e.g., condoms).
This highlights the need for a better understanding of the use of combination prevention
strategies. Additionally, among participants who reported abstinence in the previous month,
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.
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some extended gaps could have could been intentional because of no perceived risk of HIV
transmission in that period. Such practices may be logical; however, the correlation of
specific dosing patterns with achievement and maintenance of drug levels sufficient for
providing effective protection against HIV infection are unknown. Such an understanding
will be crucial in advising individuals on how to start and stop PrEP (i.e., periodic dosing)
with the confidence that it will be effective. These findings can be used in designing HIV
prevention programs with a PrEP component. For example, PrEP might not be the
recommended HIV prevention method for people who know that they will not be having sex
for certain periods. Also, individuals with outside partners may benefit from additional
counseling on risk perception and strategies for including PrEP when they are with these
other partners.
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Our study's strengths include the use of a prospective study design to assess the effects of
short-term sexual behaviors on low adherence. Our large sample size enabled us to assess
the effects of many aspects of sexual behavior. One study limitation was that few
participants reported sexual activity with both their primary and other partners. We therefore
had limited statistical power to assess associations between sexual behavior and adherence
within some strata of sexual behavior. Also, we did not have data on relationship discord, a
risk factor that has been suggested to be critical to adherence to PrEP medication 26 and
were therefore unable to evaluate possible confounding by this factor. Also, data on sexual
behavior were collected using self-report which is subject to social desirability bias, which
may result in to less reporting of some risky sexual behaviors. Lastly, we could not
distinguish if other partners were actually within polygamous marriages.
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In conclusion, our findings identify groups of people in HIV serodiscordant relationships
who may require extra adherence support during PrEP implementation programs-- namely,
those with multiple partners but are not in polygamous marriages. In addition, PrEP eligible
persons who are likely to abstain from sex may need prevention methods that are more
suitable to intermittent need. Also, we found that though overall adherence rates were high,
many participants missed taking their study pills for relatively long periods of time,
potentially creating risk for HIV acquisition. Further research is needed on the use and
efficacy of intermittent and periodic PrEP from trials and demonstration projects. We also
found that polygamy might be a factor influencing better adherence due to the desire to
prevent HIV transmission within a polygamous marriage. However, more work is needed to
ascertain this effect using a study with more people that report this behavior and one that
distinguishes whether or not the “other partner” is part of the polygamous marriage.
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Figure 1. Study populations for the Partners PrEP Study and the Ancillary Adherence Study
1Two

sites were in a rural settings and the third was in an urban setting.
for not being enrolled included participant decline, not meeting inclusion criteria
and not being offered participation into the study (after stopping of the parent clinical trial
by the DSMB)
3Fiftyfour participants excluded due of censoring the analysis dataset to before July 10 2011

2Reasons
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Table 1

Baseline characteristics of study participants (N=1093)

Author Manuscript

Characteristic
Male (N, %)

N

%

584

53.4

Age (N, %)
18-24

86

7.9

25-34

475

43.5

35-44

392

35.9

44+

140

12.8

Primary or less (≤ 7 years)

821

75.1

Secondary (8-13 years)

244

22.3

Post secondary (> 13 years)

28

2.6

Professional

66

6.0

Laborer

220

20.1

Trade/sales

148

13.5

Farming

635

58.1

Other

24

2.2

Education level (N, %)

Author Manuscript

Primary source of income (N, %)

On placebo (N, %)

387

35.4

1

0-14

Number of years living together (median, range)

8.5

0-39

Polygamous marriage (N, %)1

264

24.2

2

0-13

Duration of knowledge of discordance, years (median, range)

Number of children in partnership (median, range)
CD4 cell count in HIV-infected partner, cells/mm3 (N, %)2

Author Manuscript

< 200
200-350
> 350

30

2.8

246

22.5

817

74.7

1

Referred to one of two situations: 1) an HIV-negative man with more than one wife, one of whom was HIV-positive, or 2) an HIV-negative
woman whose HIV-infected husband had more than one wife
2

Assessed at beginning of adherence study

Author Manuscript
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Author Manuscript
Table 2

Author Manuscript

Author Manuscript
465(43)

Abstinence

92(8)

< 100% condom use

2.09

1.50
1.52-2.86

0.99-2.27

1.13-1.54

0.90-1.25

Reference

95% C.I

81(7)

< 100% condom use

0.92

0.96
0.61-1.39

0.67-1.37

60(5)
91(8)

100 % condom use

< 100% condom use

1.40

1.10
0.99-1.98

0.65-1.88

Other partner + primary partner & non-polygamous

56(5)

100 % condom use

Other partner + primary partner & polygamous4

76(7)

100 % condom use

1.32

1.06

OR

0.06

0.72

0.68

0.82

<0.01

0.06

<0.01

0.52

p-value

1.41

1.76

1.45

1.10

2.48

1.71

1.30

0.95

aOR

0.88-2.27

1.01-3.08

0.86-2.43

0.49-2.53

1.70-3.62

1.06-2.76

1.05-1.62

0.70-1.30

Reference

95% C.I

0.16

0.04

0.16

0.82

0.01

0.03

0.02

0.76

p-value

Multivariable 2
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Referred to one of two situations: 1) an HIV-negative man with more than one wife, one of whom was HIV-positive, or 2) an HIV-negative woman whose HIV-infected husband had more than one wife

4

Continuous variables

3

Low or moderate concern for HIV acquisition vs. No concern, OR 0.59 (95%C.I: 0.42-0.83)

Duration of knowledge of discordance3, OR 1.09 (95%C.I: 1.01-1.18)

Adherence study duration3, OR 1.03 (95%C.I: 1.01-1.06)

Female, OR 0.66 (95%C.I: 0.47-0.93)

Social economic status index3, OR 1.21 (95%C.I: 1.02-1.43)

Age3, OR 0.96 (95%C.I: 0.93-0.98)

Multivariable model controlled for:

2

Some participants contributed to multiple categories due to change of monthly sexual behaviors

1

418(39)

< 100% condom use

Other partner only

929(85)

N, %

100 % condom use

Primary partner only

Risk Category 1

Unadjusted

Less than 80% adherence was seen in 402 study participants during 13.3% of all follow-up months.

Author Manuscript

Univariable and multivariable analysis for < 80% adherence to PrEP
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Author Manuscript
63.4
67.4
73.1

Other only

Primary partner + other partner

36.0

<100%

83.3
85.5

Polygamous3

Non Polygamous

Polygamy status

70.5

100%

Condom use

82.7

Partner only

85.2

Prevalence

Abstinence

Sexual behavior 2

Overall 1

Description

3891 (33.3)

1088 (9.3)

1310 (11.2)

2968 (25.4)

551 (4.7)

248 (2.1)

722 (6.2)

3466 (29.6)

5001 (42.8)

Months with at least one gap (N,%)

54.8

53.8

19.4

39.2

46.3

44.9

36.6

46.4

54.7

Prevalence

1565 (13.4)

386 (3.3)

503 (4.3)

1133 (9.7)

220 (1.9)

140 (1.2)

329 (2.8)

1268 (10.8)

1966 (16.8)

Months with at least one gap (N,%)

72-hour gap

25.3

16.3

8.2

15.4

14.5

22.5

14.0

19.3

23.2

Prevalence

551 (4.7)

84 (0.7)

346 (3.0)

185 (1.6)

61 (0.5)

66 (0.6)

110 (0.9)

404 (3.5)

641 (5.5)

Months with at least one gap (N,%)

1-week gap

Referred to one of two situations: 1) an HIV-negative man with more than one wife, one of whom was HIV-positive, or 2) an HIV-negative woman whose HIV-infected husband had more than one wife

3

Sexual behavior prevalence = # participants that had at least one gap of non-adherence/# of participants that ever reported that sexual behavior

2

Overall prevalence = # of participants with at least one gap/1093.

1

Author Manuscript
48-hour gap

Author Manuscript
Table 3

Author Manuscript

Participants with gaps of non-adherence
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418(39)
465(43)

< 100% condom use

Abstinence

92(8)

< 100% condom use

1.26-2.26

0.93-2.44

1.03-1.40

0.81-1.09

Reference

95% C.I

81(7)

< 100% condom use

1.09

1.00
0.79-1.51

0.72-1.40

60(5)
91(8)

100 % condom use

< 100% condom use

1.21

1.18
0.91-1.62

0.62-2.23

Other partner + primary partner & non-polygamous

56(5)

100 % condom use

0.19

0.62

0.61

0.98

<0.01

0.09

0.02

0.43

p-value

1.07

1.17

1.16

1.01

1.50

1.32

1.17

0.91

aOR

Adherence study duration3, aOR 1.03 (95% C.I: 1.01 to 1.04)

Female, aOR 0.60 (95% C.I: 0.48 to 0.76)

Social economic status index3, aOR 1.12 (95% C.I: 1.01 to 1.25)

Age3, aOR 0.98 (95% C.I: 0.96 to 0.99)

Multivariable model controlled for:

Continuous variables

0.83-1.37

0.73-1.88

0.84-1.62

0.65-1.55

1.19-1.91

0.93-1.87

1.01-1.35

0.78-1.06

Reference

95% C.I

0.61

0.51

0.36

0.98

0.01

0.12

0.04

0.21

p-value

Multivariable 2

Referred to one of two situations: 1) either an HIV-negative man with more than one wife, one of whom was HIV-positive, or 2) an HIV-negative woman whose HIV-infected husband had more than one
wife

4

1.69

1.51

1.20

0.94

OR

Other partner + primary partner & polygamous4

76(7)

100 % condom use

Other partner only

929(85)

N, %

100 % condom use

Primary partner only

Risk Category 1

Unadjusted

Some participants contributed to multiple categories due to change of monthly sexual behaviors

2

3

Author Manuscript

1

Author Manuscript
Table 4

Author Manuscript

Univariable and multivariable analysis for having gaps of 72 hours or more without taking the study drug. Treatment gaps were observed in
598 participants during 16.8% of all follow-up months
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